InVivo Therapeutics Holdings Corp (NVIVQ)

[Perkin78]

I expected more than 10% because of the significance of the 5th patient conversion. This meets the goal of 25% conversion rate needed per the OPC to consider this study successful. Even if all subsequent patients don't see any improvement.

This alone suggests that eventual approval is highly likely if not a forgone conclusion. Sure there is still a road to travel with obstacles before commercialization. But this team has proven able to work with the FDA and continue to progress the trial forward. No reason to suggest otherwise now.

I would agree that our first trip into the mid teens was based around hype. We didn't even know what the OPC would be at that point. But conversions in 5 out of 8 evaluable patients already meeting our endpoint isn't hype, IMO it's confirmation. And should support a move up to the $9-10 range. Again IMO.